Skip to main content
The Egyptian Journal of Internal Medicine
Download PDF

Salivary α2-macroglobulin as a marker for glycemic control in patients with type 2 diabetes mellitus

The Egyptian Journal of Internal Medicine volume 31, pages 155–163 (2019)Cite this article

Abstract

Introduction

Panic from needle and the cost can discourage some diabetic patients from monitoring their blood glucose levels in a regular manner, so there is a critical need to find a new cost-effective, painless, and sensitive glucose-detection method. Many studies have found that α2-macroglobulin (A2MG) concentrations are increased in the blood of both type 1 and type 2 diabetic patients.

Aim

The aim of the article is to study the salivary A2MG value as a marker for glycemic control in patients with type 2 diabetes mellitus (DM).

Patients and methods

A total of 60 patients were included and divided into three groups. Group 1 included patients with type 2 DM with glycosylated hemoglobin (HbA1c) levels more than or equal to 7% (inadequate glycemic control). Group 2 included patients with type 2 DM with HbA1c levels less than 7% (adequate glycemic control). Group 3 included healthy persons (control group). All patients were subjected to the following: thorough history taking, full physical examination, and laboratory investigations, including fasting blood glucose, cholesterol, triglycerides, HbA1c, and salivary A2MG.

Results

There were statistical significant relations between salivary A2MG and both BMI and duration of diabetes (P<0.05) in type 2 uncontrolled diabetes group but not in controlled group (P>0.05). There were statistically significant positive correlations between levels of salivary A2MG and HbA1c, cholesterol, triglycerides, fasting blood sugar, duration of DM, BMI, and age. The best cutoff value of salivary A2MG as a predictor of bad glycemic control, in relation to HbA1c, was more than or equal to 645 ng/ml, with area under the receiver operating characteristic curve of 0.92, sensitivity of 91.7%, specificity of 90%, and P value of less than 0.001.

Conclusion and recommendation

With the advantages of rapid, accessible, sensitive, cost-effective, and noninvasive method, salivary A2MG is a promising biological marker for glycemic control in patients with type 2 DM.

References

  1. Wen J, Lin T, Cai Y, Chen Q, Chen Y, Ren Y, et al. Baduanjin exercise for type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med 2017; 2017:837821.

    Article  Google Scholar 

  2. Malkani S, Mordes JP. The implications of using hemoglobin A1C for diagnosing diabetes mellitus. Am J Med 2011; 124:395–401.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Naing C, Mak JW. Salivary glucose in monitoring glycaemia in patients with type 1 diabetes mellitus: a systematic review. J Diabetes Metab Disord 2017; 16:2.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Soares M-S-M, Batista-Filho M-M-V, Pimentel M-J, Passos I-A, Chimenos-Küstner E. Determination of salivary glucose in healthy adults. Med Oral Patol Oral Cir Bucal 2009; 14:e510–e513.

    Article  PubMed  Google Scholar 

  5. Schafer CA, Schafer JJ, Yakob M, Lima P, Camargo P, Wong DTW. Saliva diagnostics: utilizing oral fluids to determine health status. Monogr Oral Sci 2014; 24:88–98.

    Article  PubMed  Google Scholar 

  6. Atkinson HM, Parmar N, Berry LR, Chan AK. Determination of alpha-2-macroglobulin complexes by a new immuno-activity assay. Thromb Res 2012; 129:635–640.

    Article  CAS  PubMed  Google Scholar 

  7. Takada T, Kodera Y, Matsubara M. Serum monomeric alpha2-macroglobulin as a clinical biomarker in diabetes. Atherosclerosis 2013; 228:270–276.

    Article  CAS  PubMed  Google Scholar 

  8. American Diabetes Association. American Diabetes Association Standards of Medical Care in Diabetes 2018. Diabetes Care 2018; 41(Suppl. 1): S1–S159.

    Google Scholar 

  9. Farah R, Haraty H, Salame Z, Fares Y, Ojcius DM, Said Sadies N. Salivary biomarkers for the diagnosis and monitoring of neurological diseases. Biomed J 2018; 41:63–87.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Holmer HK, Ogden LA, Burda BU, Norris SL. Quality of clinical practice guidelines for glycemic control in type 2 diabetes mellitus’. PLoS ONE 2013; 8:e58625.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Khaw KT, Wareham N. Glycated hemoglobin as a marker of cardiovascular risk. Curr Opin Lipidol 2006; 17:637–643.

    Article  CAS  PubMed  Google Scholar 

  12. Milosavljevic TS, Petrovic MV, Cvetkovic ID, Grigorov II. DNA binding activity of C/EBPbeta and C/EBPdelta for the rat alpha2-macroglobulin gene promoter is regulated in an acute-phase dependent manner. Biochemistry (Mosc) 2002; 67:918–926.

    Article  CAS  Google Scholar 

  13. Campion CG, Sanchez-Ferras O, Batchu SN. Potential role of serum and urinary biomarkers in diagnosis and prognosis of diabetic nephropathy. Can J Kid Health Dis 2017; 4:1–18.

    Google Scholar 

  14. Lin Z, Lo A, Simeone DM, Ruffin MT, Lubman DM. An N-glycosylation analysis of human alpha-2-Macroglobulin using an integrated Approach. J Proteomics Bioinform 2012; 5:127–134.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Kowall B, Rathmann W, Bongaerts B, Thorand B. Are diabetes risk scores useful for the prediction of cardiovascular diseases? Assessment of seven diabetes risk scores in the KORA S4/F4 cohort study. J Diabetes Comp 2013; 27:340–345.

    Article  Google Scholar 

  16. Animaw W, Seyoum Y. Increasing prevalence of diabetes mellitus in a developing country and its related factors. PLoS One 2017; 12:e0187670.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Robinson TE, Elley CR, Kenealy T, Drury PL. Development and validation of a predictive risk model for all-cause mortality in type 2 diabetes. Diabetes Res Clin Pract 2015; 108:482–488.

    Article  PubMed  Google Scholar 

  18. Perotto M, Panero F, Gruden G, Fornengo P, Lorenzati B, Barutta F. Obesity is associated with lower mortality risk in elderly diabetic subjects: the Casale Monferrato study. Acta Diabetol 2013; 50:563–568.

    Article  CAS  PubMed  Google Scholar 

  19. Piniés JA, González-Carril F, Arteagoitia JM, Irigoien I. Development ofa prediction model for fatal and nonfatal coronary heart disease and cardiovascular disease in patients with newly diagnosed type 2 diabetes mellitus: the BasqueCountry Prospective Complications and Mortality Study risk engine (BASCORE). Diabetologia 2014; 57:2324–2333.

    Article  PubMed  Google Scholar 

  20. Shamseddeen H, Getty JZ, Hamdallah IN, Ali MR. Epidemiology and economic impact of obesity and type 2 diabetes. Surg Clin North Am 2011; 91:1163–1172.

    Article  PubMed  Google Scholar 

  21. Tsujimoto T, Kajio H. Abdominal obesity is associated with an increased risk of all cause mortality in patients with HFpEF. J Am Coll Cardiol 2017; 70:2739–2749.

    Article  PubMed  Google Scholar 

  22. Elley CR, Robinson T, Moyes SA, Kenealy T, Collins J, Robinson E, et al. Derivation and validation of a renal risk score for people with type 2 diabetes. Diabetes Care 2013; 36:3113–3120.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Chung TJ, Hsu KY, Chen JH, Liu JS, Li PF, Huang CL, et al. Association of salivary alpha 2-macroglobulin levels and clinical characteristics in type 2 diabetes. J Diabetes Investig 2015; 7:190–196.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Chung T-J, Hsu K-Y, Chen J-H, Liu J-S, Chang H-W, Li P-F, et al. Association of salivary alpha 2-macroglobulin levels and clinical characteristics in type 2 diabetes. J Diabetes Investig 2016; 7:190–196.

    Article  CAS  PubMed  Google Scholar 

  25. Rao PV, Reddy AP, Lu X, Krishnaprasad A, Biggs E, Charles T, et al. Proteomic identification of salivary biomarkers of type-2 diabetes. J Proteome Res 2009; 8:239–245.

    Article  CAS  PubMed  Google Scholar 

  26. Ahmad J, Singh M, Saleemuddin M. A study of plasma alpha-2-macroglobulin levels in type 2 diabetic subjects with microalbuminuria. J Assoc Physicians India 2001; 49:1062–1065.

    CAS  PubMed  Google Scholar 

  27. Aitken JP, Ortiz C, Morales-Bozo I, Rojas-Alcayaga G, Baeza M, Beltran C, Escobar A. Alpha-2-macroglobulin in saliva is associated with glycemic control in patients with type 2 diabetes mellitus. Dis Markers 2015; 2015:128653.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Ertugrul AS, Sahin H, Dikilitas A, Alpaslan N, Bozoglan A. Evaluation of beta-2 microglobulin and alpha-2 macroglobulin levels in patients with different periodontal diseases. Aust Dent J 2013; 58:170–175.

    Article  CAS  PubMed  Google Scholar 

  29. Border MB, Schwartz S, Carlson J, Dibble CF, Offenbacher S, Buse G, Bencharit S. Exploring salivary proteomes in edentulous patients with type 2 diabetes. Mol Biosyst 2012; 8:1304–1310.

    Article  CAS  PubMed  Google Scholar 

  30. Janice M, Christopher A, Jason J, James J, Bruce J, David T. Salivary biomarkers, toward future clinical diagnostic utilities. Clin Microbiol Rev 2013; 26:781–791.

    Article  Google Scholar 

  31. Prathibha KM, Priscilla J, Gand M, Arcot S. Evaluation of salivary profile among adult type 2 diabetes mellitus patients in south India. J Clin Diagn Res 2013; 7:1592–1595.

    Google Scholar 

  32. Abd-Elraheem SE, El saeed AM, Mansour HH. Salivary changes in type 2 diabetes patients. Diabetes Metab Synd 2017; 11S:S637–S641.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Zagazig University, Zagazig, 44519, Egypt

    Ayman Abd-Elrahman Mohamed Nsr-Allah MD

  2. Department of Clinical Pathology, Zagazig University, Zagazig, Egypt

    Saad El-Osh, Azza M. Ahmed & Sara Hazem

Authors
  1. Ayman Abd-Elrahman Mohamed Nsr-Allah MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Saad El-Osh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Azza M. Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sara Hazem
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ayman Abd-Elrahman Mohamed Nsr-Allah MD.

Additional information

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nsr-Allah, A.AE.M., El-Osh, S., Ahmed, A.M. et al. Salivary α2-macroglobulin as a marker for glycemic control in patients with type 2 diabetes mellitus. Egypt J Intern Med 31, 155–163 (2019). https://doi.org/10.4103/ejim.ejim_117_18

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/ejim.ejim_117_18

Keywords